Feed/Companies/Oricell

Oricell

As of 14 Oct 2026, Oricell has raised $110M across 1 verified round on record; latest: $110 million growth round led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and 1 other, announced 9 Apr 2026.

BUILT ON

Visit site

Oricell develops cell therapies specifically aimed at treating cancer patients, particularly through advanced CAR-T technology.

oricell.comLinkedInShanghai, ChinaBiotech

LATEST ROUND

Growth

$110M · 2026-04-09

RAISED ON RECORD · USD

$110M

across 1 verified round

INVESTORS

3 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Growthpre-IPO financing round

$110M · 2026-04-09

[ HISTORY ]

led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, Vivo Capital

Round	Amount	Announced	Lead	Buzz
Growth pre-IPO financing round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$110M	2026-04-09	Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, Vivo Capital	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source Date 2026-04-10 → 2026-04-09 · fiercebiotech.com HQ added Shanghai, China · fiercebiotech.com The headline states $110M, while the body says “over $110 million”; $110M is used, consistent with the cited company release’s financing title. Published by hand (fiercebiotech.com): "Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public": hand-checked (K, non-US): the page states the company, the equity amount and the day

Oricell

Company

Rounds

Sources

Profile

Investors

Oricell

Rounds

Profile

Sources

Growth$110M2026-04-091 source

Investors

Growth$110M2026-04-096 investors